Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 29

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 29
---
 other cash management policies or procedures that dictate how funds are transferred. We are permitted under the laws of Cayman Islands to provide funding to our subsidiaries through loans or capital contributions without restrictions on the amount of the funds. As of the date hereof, none of our subsidiaries have made any dividends or distributions to our Company and our Company has not made any dividends or distributions to our shareholders. We intend to keep any future earnings to finance the expansion of our business, and we do not anticipate that any cash dividends will be paid in the foreseeable future. Subject to the passive foreign investment company (“PFIC”) rules, the gross amount of distributions we make to investors with respect to our Class A Ordinary Shares (including the amount of any taxes withheld therefrom) will be taxable as a dividend, to the extent that the distribution is paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Company’s Strategy The Company seeks to position itself to catalyze the development and improvement of a broad range of novel and repurposed therapeutics and diagnostics across a wide range of disease/therapeutic areas. Failure to achieve positive results in at least one of the programs for a Lead Project could have a material adverse effect on the Company’s prospects and business. As such, it is important that we consistently look for promising assets which have a strong strategic fit with our core corporate direction. To achieve this goal, we are implementing the following strategies:

| ● | Selectively                                                                                                                              
 expanding our portfolio with potential products that may be able to attain orphan drug designation and/or satisfy current unmet medical  
 needs. We have selected innovations for development which we believe are of superior scientific quality, whilst taking into              
 account the potential market size and demand for same, for example, taking into consideration whether the relevant product can satisfy   
 significant unmet medical needs. In particular, Aptorum Group Limited has established a Scientific Advisory Board, which helped us to    
 select our current projects and which we expect will provide input from a scientific perspective towards any future opportunities for    
 acquiring or licensing life science innovations. We intend to continue expanding our line of projects under development, and subject     
 to our financial and other resource limitations, exploring acquisitions or licenses of additional products which may be able to attain   
 orphan drug designations (e.g., rare types of cancer) or satisfy significant unmet medical needs and that show strong preclinical and/or 
 early clinical data to provide promising opportunities for clinical and commercial success.                                              |

| ● | Collaborating                                                                                                                                     
 with